Form 4: Amicus Therapeutics Director Craig Wheeler Boosts Stake with Significant Equity and Option Grants

Amicus Therapeutics, Inc. Director Craig A. Wheeler has increased his beneficial ownership through the grant of 20,414 Restricted Stock Units and 74,872 stock options, signaling continued alignment with shareholder interests.

Summary

• Craig A. Wheeler, a Director of Amicus Therapeutics, Inc. (FOLD), acquired 20,414 shares of common stock on June 5, 2025, through the grant of Restricted Stock Units (RSUs).
• These RSUs were granted at a price of $0.0 and will vest in full on the one-year anniversary of the grant date, with each RSU equivalent to one share of common stock.
• Following this transaction, Mr. Wheeler directly beneficially owns 84,631 shares of common stock.
• Additionally, Mr. Wheeler was granted 74,872 stock options on June 5, 2025, with an exercise price of $5.96 per share.
• These stock options were granted at a price of $0.0 and will become 100% exercisable on the one-year anniversary of the grant date (June 5, 2026), expiring on June 5, 2035.
• After this transaction, Mr. Wheeler directly beneficially owns 74,872 stock options.

Sentiment

Score: 8

Explanation: The acquisition of a significant number of shares and options by a director, particularly through grants, is generally viewed positively as it indicates strong insider confidence and aligns management's interests with long-term shareholder value. It suggests a belief in the company's future prospects.

Positives

• The acquisition of 20,414 Restricted Stock Units (RSUs) and 74,872 stock options by a director indicates strong confidence in the company's future performance.
• The grants, at a price of $0.0, represent a direct increase in the director's stake without personal cash outlay at the time of grant, aligning his interests with long-term shareholder value.
• The vesting schedule (one-year anniversary) encourages long-term commitment and performance from the director.

Negatives

• No direct negatives are apparent from this Form 4 filing, as it reports an acquisition of equity and options by an insider.

Risks

• The value of the granted RSUs and stock options is tied to the future performance of Amicus Therapeutics' common stock, meaning their ultimate value could decrease if the stock price declines.
• The stock options have an exercise price of $5.96, meaning they would be "out of the money" if the stock price falls below this level, reducing their intrinsic value.

Future Outlook

The grants of Restricted Stock Units and stock options with a one-year vesting period suggest an expectation of continued service and performance from the director, aligning his incentives with the company's long-term growth strategy.

Industry Context

This insider transaction is typical for executive and director compensation in the biotechnology and pharmaceutical industries, where equity grants are commonly used to align management incentives with long-term shareholder value and to retain key talent. Such grants are a standard component of compensation packages designed to motivate performance and foster commitment to the company's strategic objectives, particularly in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) and stock options as a form of director compensation is a common practice across the biotechnology and pharmaceutical sectors, aligning with industry standards for incentivizing long-term performance.
• The vesting period of one year for both RSUs and stock options is a standard approach to ensure continued commitment and performance from directors, comparable to practices observed at companies like BioMarin Pharmaceutical Inc. or Sarepta Therapeutics, Inc., which also utilize similar equity-based compensation structures for their board members.
• The grant price of $0.0 for RSUs and options is typical for compensatory grants, reflecting their nature as performance or retention incentives rather than direct purchases.

Related Party Transactions

• This filing details a related party transaction, specifically the grant of equity compensation (Restricted Stock Units and stock options) to Craig A. Wheeler, a Director of Amicus Therapeutics, Inc.

Stakeholder Impact

• Shareholders: The grants align the director's financial interests with those of the shareholders, potentially leading to more focused efforts on increasing shareholder value. It could be perceived as a positive signal of insider confidence.
• Employees: While not directly impacting employees, such compensation structures for leadership can reflect a broader company philosophy on performance-based incentives.

Next Steps

• The 20,414 Restricted Stock Units (RSUs) will vest in full on June 5, 2026.
• The 74,872 stock options will become 100% exercisable on June 5, 2026.

Key Dates

Recommendation

Keywords

Amicus Therapeutics, FOLD, SEC Form 4, Insider Trading, Stock Grant, Restricted Stock Units, RSUs, Stock Options, Director Compensation, Equity Compensation, Beneficial Ownership, Biotechnology, Pharmaceuticals